A Food and Drug Administration panel on Wednesday advocated for regulatory changes that would make testosterone medications more widely accessible, including removing their classification as controlled substances and changing product labels to expand eligibility.

The 13-person panel — composed primarily of urologists and federal health officials — gave a resounding endorsement of testosterone replacement therapy, a treatment for men whose bodies don’t produce enough of the hormone. The experts said the therapy, known informally as TRT, has been underutilized due to outdated concerns about risks of prostate cancer, stroke and heart disease .

“Testosterone is still regulated as if it were a dangerous, performance-enhancing drug from the athletic doping scandals of the 1980s. And because

See Full Page